Literature DB >> 16298531

Mice lacking alpha-synuclein are resistant to mitochondrial toxins.

Peter Klivenyi1, Donald Siwek, Gabrielle Gardian, Lichuan Yang, Anatoly Starkov, Carine Cleren, Robert J Ferrante, Neil W Kowall, Asa Abeliovich, M Flint Beal.   

Abstract

Abnormalities in the function of alpha-synuclein are implicated in the pathogenesis of Parkinson's disease (PD). We found that alpha-synuclein-deficient mice are resistant to MPTP-induced degeneration of dopaminergic neurons. There was dose-dependent protection against loss of both dopamine in the striatum and dopamine transporter (DAT) immunoreactive neurons in the substantia nigra. These effects were not due to alterations in MPTP processing. We found that alpha-synuclein-deficient mice are also resistant to both malonate and 3-nitropropionic acid (3-NP) neurotoxicity. There was reduced generation of reactive oxygen species in alpha-synuclein-deficient mice following administration of 3-NP. These findings implicate alpha-synuclein as a modulator of oxidative damage, which has been implicated in neuronal death produced by MPTP and other mitochondrial toxins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16298531     DOI: 10.1016/j.nbd.2005.08.018

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  85 in total

Review 1.  Parkinson's disease: a rethink of rodent models.

Authors:  Heather L Melrose; Sarah J Lincoln; Glenn M Tyndall; Matthew J Farrer
Journal:  Exp Brain Res       Date:  2006-04-26       Impact factor: 1.972

Review 2.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

3.  A Western-like fat diet is sufficient to induce a gradual enhancement in fat mass over generations.

Authors:  Florence Massiera; Pascal Barbry; Philippe Guesnet; Aurélie Joly; Serge Luquet; Chimène Moreilhon-Brest; Tala Mohsen-Kanson; Ez-Zoubir Amri; Gérard Ailhaud
Journal:  J Lipid Res       Date:  2010-04-20       Impact factor: 5.922

Review 4.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

5.  Synergistic effects of environmental risk factors and gene mutations in Parkinson's disease accelerate age-related neurodegeneration.

Authors:  Jun Peng; May Lin Oo; Julie K Andersen
Journal:  J Neurochem       Date:  2010-11-04       Impact factor: 5.372

Review 6.  Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis.

Authors:  Rebecca Banerjee; Anatoly A Starkov; M Flint Beal; Bobby Thomas
Journal:  Biochim Biophys Acta       Date:  2008-11-14

7.  Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein.

Authors:  Wai Haung Yu; Yasuji Matsuoka; István Sziráki; Audrey Hashim; John Lafrancois; Henry Sershen; Karen E Duff
Journal:  Neurochem Res       Date:  2007-11-13       Impact factor: 3.996

Review 8.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 9.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

10.  The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition.

Authors:  Virginie Loeb; Eugenia Yakunin; Ann Saada; Ronit Sharon
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.